Clinical trials: Tryptase
Anaphylaxis, Hypotension
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis
Background: Omalizumab is an approved drug for the treatment of asthma by the Food and Drug Administration. Researchers are now studying this drug in a double-blind placebo-controlled manner to assess efficacy in patients with…
- Conditions
- Anaphylaxis, Hypotension, Bronchospasm, Angioedema
- Trial name
- NCT00890162
- Testing
- Epinephrine, Omalizumab (Xolair)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)